NeuroSoV

Given that Parkinson’s disease (PD) is growing exponentially, it is even more important to take attention to the facts that PD may become one of the major health problems of the century and no one is immune to it (Todd Sherer, MJFox Foundation CEO, on Journal of Parkinson’s Disease 8, 2018). PD is a chronic neurodegenerative disorder that targets medium aged people (average 53 years) with no treatment so far. Currently, there are approximately 10 million PD patients in need of new therapies. NeuroSoV is dedicated to the development of therapies targeted at slowing down PD pathologic progression. According to the MJ Fox Foundations 2019 Report the total annual economic burden of PD is approximately $52 billion in USA and ~€12.5 billion in Europe. PD’s causes are associated with both environmental and genetic factors. Such factors induce Mitochondrial dysfunction, Inflammation, and oxidative stress, among other mechanisms of disease, leading to dopaminergic neuronal death. To address this problem our team developed a new drug candidate for PD, that targets an enzyme that contribute for the oxidative stress pathologic mechanism in PD. This approach has the potential to halt the progression of Parkinson's Disease. Our approach will impact both PD and the drug development fields launching innovative solutions to develop new or to reformulate old symptomatic therapies. Moreover, it will launch a new avenue of research to make available additional new therapies to halt the progression of PD, improving PD patient’s quality of life, and having a high socio-economic impact. The reformulation technology may also be used by pharmaceutical companies in the development of additional therapies for other neurological disorders. Currently, NeuroSoV has other molecules in its pipeline that we want to keep developing. Founded in early 2020, NeuroSoV has performed the reformulation and characterization of the molecule and is testing its efficacy in PD models. The company’s goal is to license the molecule to a pharmaceutical company once the pre-clinical validation is completed.